Recognizing the potential for human genetics and precision chemistry to disrupt the drug discovery paradigm, Eisai recently announced establishment of the new Eisai Center for Genetics Guided Dementia Discovery (G2D2). This industry-unique center will occupy a purpose-designed state-of-the-art 50,000 sq. ft. research facility in Cambridge, MA currently scheduled to be completed in spring 2019. The mission of the new center is to accelerate drug discovery and development using human genetics to drive multi-disciplinary team-based progress towards medicines that address unmet patient needs. The predominant research focus of G2D2 will be immunodementia: a new concept for next-generation therapeutics for Alzheimer’s Disease and other dementias that targets immune/inflammation related mechanisms. Our approach is premised upon and continuously incorporates robust insights from human genetics and other sources of human biology. This research focus builds upon Eisai’s considerable experience in and commitment to neurology research, and to our human health care mission which recognizes the profound impact of Alzheimer’s and related dementia on patients and their caregivers. More information about G2D2 is provided here (http://eisai.mediaroom.com/2018-06-12-Eisai-Inc-to-Launch-Center-for-Genetics-Guided-Dementia-Discovery-in-Cambridge-Massachusetts), and about Eisai’s Neurology strategy and pipeline are provided here (https://www.eisai.com/index.html)
You will join a highly interactive and collaborative team spanning a broad range of drug discovery capabilities including: data sciences (genetics and informatics), wet lab biology (in-vitro and in-vivo), drug discovery platforms (biochemistry, chemical biology, assay development, structural biology, screening, drug safety and DMPK), and chemistry (including application of novel small molecule and anti-sense oligonucleotide approaches). At Eisai, we highly value both internal and external collaboration and pursue flexible research models with a range of external scientific partners to accelerate delivery of innovative medicines. As an Eisai employee you will also spend at least 1% of your working time with patients and families to ensure that the innovation you drive is based on an understanding of their real needs.
G2D2 builds upon the success of the Eisai AiM Institute (described here: www.EisaiUS-AIM.com). This role will initially be located at the Eisai AiM Institute in Andover, MA, and you will be a key part of our transition to the new center in Cambridge (this transition is scheduled to be completed by spring 2019).
The Scientist, Chemical Biology is expected to work independently to perform and analyze chemical biology and proteomic assays in a team environment focusing on early stage drug discovery. The incumbent is expected to work closely with structure biologists, chemists, data scientists, and cell biologists during the design and implementation of the assays. This position requires expertise in chemical biology and proteomics, ideally in the areas of neuroscience and immune-biology. Strong communication skills are required, and a broader understanding of the drug discovery process is a plus.
1. Design and develop highly effective biochemical probes for in vitro and in vivo assay development
2. Establish cell-free and cell-based assays to evaluate macromolecule targeting and modification
3. Work closely with both biology and chemistry teams to develop quantitative mass spectrometry-based proteomics studies
4. Analyze, interpret, and deliver results in timely fashion
5. Communicate effectively with internal and external collaborators to achieve company objectives
6. Work effectively in multi-disciplinary team environment
• Must have a Ph.D. with post-doctoral research experience in relevant fields including probe design, macromolecule modification, and mass spectrometry-based quantitative proteomics.
• Experience with state-of-the-art mass spectrometry-based proteomics, including experiment design, method development, and data analysis
• Experience with probe design and various detection methods such as fluorescence-based detection
• Good understanding and experience in cell biology
• Proactively evaluate and implement new technologies to advance our drug discovery projects
•The ability to work in our Andover, MA office until the move to Cambridge, MA occurs, anticipated to be Spring of 2019